Payment overview · 2025
General Payments
$145.28
4 reported records · 3 companies
Healthcare provider profile · identity verified
Ramesh Sabapathi, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BALTIMORE, MD · NPI 1730118993
Verified facts
What the public records show
CMS Open Payments records show Ramesh Sabapathi, MD received $145.28 in general payments during 2025 across 4 reported records.
Teva Pharmaceuticals USA, Inc. accounted for 74.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $108.12 | 74.4% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.89 | 14.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.27 | 11.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Education | $91.25 | 1 |
| Food and Beverage | $54.03 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.89 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $16.87 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.27 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.27 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
134 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 590 | 113 |
| Amlodipine Besylate | Amlodipine Besylate | 480 | 84 |
| Gabapentin | Gabapentin | 320 | 53 |
| Levothyroxine Sodium | Levothyroxine Sodium | 298 | 44 |
| Eliquis | Apixaban | 273 | 37 |
| Omeprazole | Omeprazole | 215 | 38 |
| Losartan Potassium | Losartan Potassium | 211 | 42 |
| Lisinopril | Lisinopril | 197 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 191 | 31 |
| Trazodone Hcl | Trazodone Hcl | 189 | 33 |
| Pantoprazole Sodium | Pantoprazole Sodium | 187 | 42 |
| Furosemide | Furosemide | 184 | 39 |
| Metformin Hcl | Metformin Hcl | 158 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 155 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 144 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 137 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 136 | 28 |
| Jardiance | Empagliflozin | 134 | 16 |
| Sertraline Hcl | Sertraline Hcl | 128 | 17 |
| Olanzapine | Olanzapine | 119 | 13 |
| Atenolol | Atenolol | 117 | 21 |
| Memantine Hcl | Memantine Hcl | 116 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 113 | 15 |
| Xarelto | Rivaroxaban | 112 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 109 | 32 |
| Mirtazapine | Mirtazapine | 109 | 23 |
| Levetiracetam | Levetiracetam | 107 | 17 |
| Famotidine | Famotidine | 92 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 90 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 90 | 17 |
| Divalproex Sodium | Divalproex Sodium | 89 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 89 | 14 |
| Simvastatin | Simvastatin | 88 | 20 |
| Carvedilol | Carvedilol | 86 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 81 | 15 |
| Montelukast Sodium | Montelukast Sodium | 80 | 12 |
| Ozempic | Semaglutide | 79 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 75 | 13 |
| Ibuprofen | Ibuprofen | 71 | 22 |
| Warfarin Sodium | Warfarin Sodium | 69 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 66 | 16 |
| Potassium Chloride | Potassium Chloride | 65 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 62 | 11 |
| Metformin Hcl Er | Metformin Hcl | 59 | 14 |
| Nifedipine Er | Nifedipine | 59 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 57 | 19 |
| Baclofen | Baclofen | 56 | 12 |
| Risperidone | Risperidone | 54 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 50 | suppressed |
| Meloxicam | Meloxicam | 50 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 46 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | suppressed |
| Latanoprost | Latanoprost | 45 | 13 |
| Finasteride | Finasteride | 44 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 43 | 14 |
| Ezetimibe | Ezetimibe | 43 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 42 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 41 | 19 |
| Januvia | Sitagliptin Phosphate | 41 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 38 | 11 |
| Ranolazine Er | Ranolazine | 37 | suppressed |
| Allopurinol | Allopurinol | 36 | suppressed |
| Topiramate | Topiramate | 35 | suppressed |
| Gemtesa | Vibegron | 33 | suppressed |
| Prednisone | Prednisone | 33 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 32 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 32 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 21 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 31 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 31 | suppressed |
| Lacosamide | Lacosamide | 31 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | suppressed |
| Lidocaine | Lidocaine | 30 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 30 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 29 | suppressed |
| Glipizide | Glipizide | 29 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 19 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 27 | 26 |
| Divalproex Sodium Er | Divalproex Sodium | 27 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 25 | suppressed |
| Amoxicillin | Amoxicillin | 25 | 15 |
| Ketoconazole | Ketoconazole | 24 | 12 |
| Nyamyc | Nystatin | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 23 | suppressed |
| Spironolactone | Spironolactone | 23 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 22 | suppressed |
| Entresto | Sacubitril/Valsartan | 22 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 11 |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 21 | suppressed |
| Tradjenta | Linagliptin | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 20 | 12 |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Nystatin | Nystatin | 19 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 19 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 19 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Lorazepam | Lorazepam | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Azithromycin | Azithromycin | 17 | 15 |
| Carbamazepine | Carbamazepine | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 12 |
| Glipizide Er | Glipizide | 17 | suppressed |
| Vascepa | Icosapent Ethyl | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Haloperidol | Haloperidol | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Constulose | Lactulose | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 13 | suppressed |
| Valproic Acid | Valproic Acid | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 12 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Lumigan | Bimatoprost | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Perphenazine | Perphenazine | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $145.28 · 4 records | Teva Pharmaceuticals USA, Inc. | AUSTEDO XR, Cologuard Collection Kit, MOUNJARO, ZEPBOUND | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error